Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium: Frontiers in research review: Physiological and pathological functions of high-density lipoprotein

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 7, 2010, Pages 736-742

  Andrews, Karen L ^a   Moore, Xiao L ^a   Chin Dusting, Jaye Pf ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

atherosclerosis; endothelial nitric oxide synthase; endothelial progenitor cells; endothelium; high density lipoprotein; nitric oxide

Indexed keywords

APOLIPOPROTEIN A1; CASPASE 3; CAVEOLIN; CD133 ANTIGEN; CD34 ANTIGEN; CELL MARKER; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; NITRIC OXIDE; SCAVENGER RECEPTOR BI; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TORCETRAPIB; VASCULOTROPIN RECEPTOR 2; ANTIINFLAMMATORY AGENT; FIBRINOLYTIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL FUNCTION; CHOLESTEROL TRANSPORT; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL STEM CELL; GENE THERAPY; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; STEM CELL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOSYNTHESIS; METABOLISM; MOUSE; PHYSIOLOGY; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS, HDL; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; STEM CELLS; THROMBOSIS;

EID: 77953815629     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05387.x     Document Type: Review

References (73)

1. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: Subsets and functions. Nat. Rev. Cardiol. 2010 7: 77 86.
2. Kostner G, Alaupovic P. Studies of the composition and structure of plasma lipoproteins. Separation and quantification of the lipoprotein families occurring in the high density lipoproteins of human plasma. Biochemistry 1972 11: 3419 3428.
3. Silva RA, Huang R, Morris J et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc. Natl Acad. Sci. USA 2008 105: 12176 12181.
4. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta 1981 665: 408 419.
5. Catte A, Patterson JC, Jones MK et al. Novel changes in discoidal high density lipoprotein morphology: A molecular dynamics study. Biophys. J. 2006 90: 4345 4360.
6. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol. 2001 38: 163 169.
7. Hoang A, Murphy AJ, Coughlan MT et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007 50: 1770 1779.
8. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux. Implications for the treatment of atherosclerosis. Cell Metab. 2008 7: 365 375.
9. Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ. J. 2009 73: 595 601.
10. Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 1986 315: 1046 1051.
11. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998 97: 2494 2498.
12. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am. J. Cardiol. 2000 86: L19 22.
13. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986 256: 2835 2838.
14. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 1977 62: 707 714.
15. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 2007 357: 1301 1310.
16. Li XP, Zhao SP, Zhang XY, Liu L, Gao M, Zhou QC. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int. J. Cardiol. 2000 73: 231 236.
17. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc. Natl Acad. Sci. USA 1996 93: 9114 9119.
18. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ. Res. 1995 76: 980 986.
19. Navab M, Imes SS, Hama SY et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 1991 88: 2039 2046.
20. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995 15: 1987 1994.
21. Shaw JA, Bobik A, Murphy A et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 2008 103: 1084 1091.
22. Kimura T, Tomura H, Mogi C et al. Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell. Signal. 2006 18: 841 850.
23. Kimura T, Tomura H, Sato K et al. Mechanism and role of high-density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J. Biol. Chem. 2010 285: 4387 4397.
24. Kimura T, Sato K, Kuwabara A et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 2001 276: 31780 31785.
25. Nofer JR, van der Giet M, Tolle M et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004 113: 569 581.
26. Xia P, Gamble JR, Rye KA et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc. Natl Acad. Sci. USA 1998 95: 14196 14201.
27. Theilmeier G, Schmidt C, Herrmann J et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006 114: 1403 1409.
28. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001 345: 1583 1592.
29. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 110: 3512 3517.
30. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J. 2002 144: 165 172.
31. Armitage J, Baigent C, Chen Z, Landray M. A Randomized Trial of the Long-Term Clinical Effects of Raising HDL Cholesterol with Extended Release Niacin/Laropiprant. 2007. Available from: http://clinicaltrialsfeeds.org/ clinical-trials/show/NCT00461630 (accessed 5 May 2010).
32. Brown BG, Boden WE. AIM HIGH; Niacin Plus Statin to Prevent Vascular Events. 2009. Available from http://clinicaltrials.gov/ct2/show/NCT00120289 (accessed 5 May 2010).
33. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 2004 350: 1505 1515.
34. Clark RW, Sutfin TA, Ruggeri RB et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 2004 24: 490 497.
35. Nissen SE, Tardif JC, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 2007 356: 1304 1316.
36. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007 357: 2109 2122.
37. Spieker LE, Sudano I, Hurlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002 105: 1399 1402.
38. Bisoendial RJ, Hovingh GK, Levels JH et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003 107: 2944 2948.
39. Napoli C, de Nigris F, Williams-Ignarro S et al. Nitric oxide and atherosclerosis: An update. Nitric Oxide 2006 15: 265 279.
40. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000 101: 1899 1906.
41. Vasquez-Vivar J, Kalyanaraman B, Martasek P et al. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc. Natl Acad. Sci. USA 1998 95: 9220 9225. (Pubitemid 28506212)
42. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J. Biol. Chem. 1999 274: 32512 32519.
43. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J. Biol. Chem. 1996 271: 22810 22814.
44. Mineo C, Shaul PW. HDL stimulation of endothelial nitric oxide synthase. A novel mechanism of HDL action. Trends Cardiovasc. Med. 2003 13: 226 231.
45. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 2000 275: 11278 11283.
46. Yuhanna IS, Zhu Y, Cox BE et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 2001 7: 853 857.
47. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J. Clin. Invest. 1999 103: 897 905.
48. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-) Apoe(-/-) mice are ameliorated by enalapril treatment. J. Clin. Invest. 2000 105: 451 458.
49. Ozaki M, Kawashima S, Yamashita T et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J. Clin. Invest. 2002 110: 331 340.
50. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J. Mol. Cell. Cardiol. 2007 42: 271 279.
51. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 2003 278: 9142 9149.
52. Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl Acad. Sci. USA 2004 101: 6999 7004.
53. Ramet ME, Ramet M, Lu Q et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol. 2003 41: 2288 2297.
54. Li XA, Titlow WB, Jackson BA et al. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J. Biol. Chem. 2002 277: 11058 11063.
55. Igarashi J, Thatte HS, Prabhakar P, Golan DE, Michel T. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc. Natl Acad. Sci. USA 1999 96: 12583 12588. (Pubitemid 29513545)
56. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta 2000 1485: 63 99.
57. Lee CM, Chien CT, Chang PY et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity. Atherosclerosis 2005 183: 251 258.
58. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol. 2007 150: 470 479.
59. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997 275: 964 967.
60. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002 105: 3017 3024.
61. Werner N, Priller J, Laufs U et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: Effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol. 2002 22: 1567 1572.
62. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J. Am. Coll. Cardiol. 2007 49: 741 752.
63. Yamahara K, Itoh H. Potential use of endothelial progenitor cells for regeneration of the vasculature. Ther. Adv. Cardiovasc. Dis. 2009 3: 17 27.
64. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin. Sci. 2004 107: 273 280.
65. Pirro M, Schillaci G, Paltriccia R et al. Increased ratio of CD31+/CD42-microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2006 26: 2530 2535.
66. Pellegatta F, Bragheri M, Grigore L et al. In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. Int. J. Mol. Med. 2006 17: 203 208.
67. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol. 2006 26: 1144 1149.
68. Sumi M, Sata M, Miura S et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2007 27: 813 818.
69. Noor R, Shuaib U, Wang CX et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis 2007 192: 92 9.
70. Feng Y, van Eck M, Van Craeyveld E et al. Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood 2009 113: 755 764.
71. Sbaa E, Dewever J, Martinive P et al. Caveolin plays a central role in endothelial progenitor cell mobilization and homing in SDF-1-driven postischemic vasculogenesis. Circ. Res. 2006 98: 1219 1227.
72. Walter DH, Rochwalsky U, Reinhold J et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler. Thromb. Vasc. Biol. 2007 27: 275 282.
73. Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 1995 96: 2758 2767.